Unknown OBSERVATIONAL NCT05310357

Chromosomal Instability in Ovarian Cancer

The Role of Chromosomal Instability in Monitoring the Course of Ovarian High-grade Serous Carcinoma

Sponsor: Lei Li

Conditions Chromosomal Instability Epithelial Ovarian Cancer High-grade Serous Ovarian Carcinoma Minimal Residual Lesions Overall Survival Progression-free Survival Somatic Copy Number Distortion Survival Outcomes

Interventions Testing for chromosomal instability (CIN)

Updated 4 times since 2022 Last updated: Mar 26, 2022 Started: Mar 26, 2022 Primary completion: Mar 26, 2023 Completion: Mar 26, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chromosomal Instability and Epithelial Ovarian Cancer and is currently ongoing. Lei Li leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
May 2022 — Apr 2024 [monthly]

Recruiting

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lei Li

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China